Theraputic target for prostate cancer

Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson. John W. Pepper proposes a new strategy in the arms race between humans and germs– targeting the teamwork within

Full Post: New approach to stopping germs

The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.

Hormone-related therapy is the first line of treatment for more advanced prostate cancers as prostate cancer cells usually rely on male hormones to grow. Some prostate cancers become insensitive to hormone-related therapy after initially responding to it.

Over the past 50 years, the dietary intake of omega-6 fatty acids has increased substantially, relative to that of omega-3 fatty acids, in Western countries.

We are what we eat - dietary omega-6 fatty acids end up in our cells where they are released by the enzyme cPLA2- and converted into inflammatory chemicals. Inflammatory chemicals can contribute to the development and progression of prostate cancer due to their roles in promoting cell and blood vessel growth.

Dr Qihan Dong and his research group hypothesised that, since a reduction of omega-6 or an increase in omega-3 fatty acid intake might decrease prostate cancer development and progression, blocking cPLA2- activity could have a therapeutic effect in treating advanced prostate cancer.

“cPLA2- is found in all prostate cancer cells. Not only is cPLA2- increased in hormone-insensitive cells; inhibition of cPLA2- results in a significant reduction in prostate cancer cell numbers, due to reduced proliferation (cell growth) and increased apoptosis (cell death),” said co-author Dr Qihan Dong from the University of Sydney. Drugs that inhibit cPLA2- could be effective in treating hormone refractory prostate cancer.


The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of

Full Post: FDA approves injectable drug degarelix for advanced prostate cancer

Moderate alcohol intake is associated with higher levels of omega-3 fatty acids in plasma and red blood cells. This is the major finding of the European study IMMIDIET that will be published in the January issue of the American Journal of Clinical Nutrition, an official publication of the American Society for Nutrition and is already

Full Post: Moderate alcohol intake boosts amount of omega-3 fatty acids in our body

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. The findings,

Full Post: Why prostate cancer patients fail hormone deprivation therapy

DHEA is a natural circulating hormone and the body’s production of it decreases with age. Men take DHEA as an over-the-counter supplement because it has been suggested that DHEA can reverse aging or have anabolic effects since it can be metabolized in the body to androgens. Increased consumption of dietary isoflavones is associated with a

Full Post: New evidence suggests preventive effect of herbal supplement in prostate cancer

A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women. Stuart Quan, MD, division of sleep medicine at

Full Post: People with severe obstructive sleep apnea often have poor diets